Allergy Therapeutics (LON:AGY) Trading 2.2% Higher – Here’s Why

Allergy Therapeutics plc (LON:AGY)’s stock price rose 2.2% during trading on Tuesday . The company traded as high as GBX 6.50 ($0.08) and last traded at GBX 5.93 ($0.07). Approximately 318,980 shares changed hands during mid-day trading, a decline of 42% from the average daily volume of 551,773 shares. The stock had previously closed at GBX 5.80 ($0.07).

Allergy Therapeutics Price Performance

The company has a quick ratio of 1.48, a current ratio of 1.40 and a debt-to-equity ratio of 37.22. The company has a market cap of £310.05 million, a PE ratio of -108.33, a P/E/G ratio of -30.70 and a beta of 1.40. The stock has a 50-day simple moving average of GBX 6.54 and a 200 day simple moving average of GBX 5.42.

Allergy Therapeutics (LON:AGY) last released its quarterly earnings data on Wednesday, November 6th. The company reported GBX (1.07) (($0.01)) earnings per share (EPS) for the quarter. Allergy Therapeutics had a negative return on equity of 155.90% and a negative net margin of 94.29%. Equities analysts expect that Allergy Therapeutics plc will post -2.56 EPS for the current year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.